Novartis Interested in Expanding Globally in Vaccines, FuW Says

Novartis AG’s vaccine unit is interested in acquisitions that enable global expansion rather those that provide new products, Finanz und Wirtschaft said, citing an interview with the unit’s head, Andrin Oswald.

The size of a possible acquisition could be between $100 million and $200 million, the newspaper cited Oswald as saying. Novartis doesn’t need to buy vaccine products because it has a full pipeline, Oswald is quoted as saying in the newspaper.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net;

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.